	OCT-04-2007 📆:27 From:GSK			919 483 5730		0	P.1/2	
		OIPE	PART	B - FEE(S) TRÀNS	SMITTAL			
	Complete and se	end this form, togetl	မွှင့် ဗ	C P. A	fail Stop ISSD-4'EE commissioner for Pate O. Box 1450 lexandria, Virginia 2 571)-273-2885	ents		
INSTRUCTIONS: This form should be used for Edosmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed we appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address indicated unless corrected below or directly described by the patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address; maintenance fee notifications.								
	CURRENT CORRESPOND	DENCE ADDRESS (Note: Use Bio	ock I for any change of address)	Fo	ote: A certificate of mailing ce(s) Transmittal. This certifupers. Each additional paper	care exittot be used for a	omestic mailings of the ny other accompanying of formal drawing, mus	
23347 7590 07/09/2007 buve its own certificate of mailing or transmission.  CLAXOSMITHK! INE							_t	
	GLAXOSMITHKLINE  CORPORATE INTELLECTUAL PROPERTY, MAI B475  FIVE MOORE DR., PO BOX 13398  RESEARCH TRIANGLE PARK, NC 27709-3398  RESEARCH TRIANGLE PARK, NC 27709-3398							
	•		Q 27707 2270	<u> </u>	<u> Valerie L</u>	. Phillips	(Depositor's name)	
10/04/	2007 FMETEKI2 000	00131 071392 1000	7272	<u>-</u>	Yaleree 7	Chillyn	(Signature)	
01 FC	1501 1440 00 1504PPLICATION NO.	G. B.O		L		-	(Date)	
03 FC:	1004 PPLICATION 000 00 00 00 00 00 00 00 00 00 00 00 0	· · · · · · · · · · · · · · · · · · ·	<u>l</u>	Bobby Neal Glover	ORATTO	RNEY DOCKET NO. C	ONFIRMATION NO.	
TITLE OF INVENTION: NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND								
[	APPLN. TYPE	SMAL). RNTITY	ISSUE FEE DUE	PUBLICATION FER DUE	PREV. PAID ISSUB FEE	TOTAL FER(S) DUE	DATE DUE	
	nonprovisional	NO	\$1400	\$300	\$0	\$1700	10/09/2007	
[	EXAM	INER	ART UNIT	CLASS-SUBCLASS	7			
	JIANG, SHAOJIA A 1623			536-043000	•••			
	CFR 1.363).  Change of corresp Address form PT()/Si  "Fee Address" ind	ence address or indication condence address (or Char B/122) attached. lication (or "Fee Address" 02 or mure recent) attached	age of Correspondence	(I) the names of up (or agents OR, alternate) (2) the name of a single	patent front page, list to 3 registered patent attorn tively, gle firm (having as a member agent) and the names of up torneys or agents. If no nam ic printed.	rra Z	nn Morgan	
3		ND RESIDENCE DATA						
	PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.							
	(A) NAME OF ASSI	GNEE	Λ	(B) RESIDENCE: (CIT	Y and STATE OR COUNT	RY)		
	Smithkline Beecham Corporation Philadelphia, PA							
<u> </u>	Please check the appropriate assignce category or categories (will not be printed on the patent): Individual Corporation or other private group entity.							
4u. The following fee(s) are submitted: 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)							vii above)	
	Selection Fee (No small entity discount permitted)			☐ A check is enclosed. ☐ Payment by credit or	urd. Form PTO-2038 is aga	ched		
	Advance Order - # of Copies 4			The Director is hereby authorized to charge the required fuc(s), any deficiency, or credit any overpayment, to Deposit Account Number 07-1392 (enclose an extra copy of this form).				
5		tus (from status indicated						
a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  NOTE: The Issue Fee and Publication Fee (If required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignce or other printerest as shown by the records of the United States Putent and Trudemark Office.							.27(g)(2).	
<u>i</u>	NOTE: The Issue Fee an aterest as shown by the i	d Publication Fee (if requirecords of the United State	ired) will not be accepte as Putent and Trudeman	od from anyone other than of Office.	the applicant; a registered a	llorney or agent; or the as	signce or other party in	
	Authorized Signature	Ser	2		Date FOCH	2007		
	Typed or printed name	e Lorie Ann	Morgan		Registration No. 3	<u>8, 181</u>		
7	his collection of inform	ation is required by 37 CI	R 1.311. The informati	on is remited to obtain up	retain a henefit by the aubli		A. LIGITOR	

Inis collection of information is required by 37 CFR 131. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the annual of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.